[Hypertrichosis and gingival hypertrophy regression in renal transplants following the substitution of cyclosporin by tacrolimus].
Gingival Hyperplasia (GH) and hypertrichosis (HT) are two sides effects associated with the usage of cyclosporine (CyA) but not with tacrolimus (FK 506). The aim of this study is to evaluate the efficacy and security of the conversion from CsA to FK 506 to treat those two complications. From August 1996 to May 1997, 15 patients (9 males, 6 females) aged from 23 to 63 years old (38 +/- 14, mean +/- SD) were switched from CsA to FK 506, 12 for GH, 2 for HT and one for combined presentation. FK 506 was first initiated at a dose of 0.15 mg/kg/day and then adjusted to a level target of 8 ng/ml. The conversion was done on an out patient basis at average 35 (5-83) months after transplantation. Patients were followed prospectively for 12 months. There was a significant reduction in GH in all patients within 3 months. Five out 13 patients had a complete resolution of GH within three months of conversion, 9/12 within 6 months and all by 12 months. HT resolved completely within 6 months. No rejection episode occurred and the serum creatinin remain stable over one year post conversion. Conversion from CsA to FK 506 is thus a safe and valid option to treat CsA induced GH and HT.
Busque
S
S
Service de Chirurgie, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Sherbrooke, Québec, Canada.
Demers
P
P
Saint-Louis
G
G
Boily
J G
JG
Tousignant
J
J
Lemieux
F
F
Martin
G
G
Smeesters
C
C
Corman
J
J
Daloze
P
P
D000328:Adult; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D016903:Drug Monitoring; D005260:Female; D005885:Gingival Hyperplasia / Q000139:chemically induced*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus
Régression de l'hypertrichose et de l'hypertrophie gingivale chez des greffés rénaux suite à la substitution de la cyclosporine par le tacrolimus.